| Source: |
| Type: |
| The effectiveness of chemotherapy by increasing cancer cell sensitivity to the drugs used to treat them, which is known as “chemo-sensitization”. Possible Chemo-Sensitizers: -Curcumin -Resveratrol -EGCG -Quercetin -Genistein -Berberine -Piperine: alkaloid from black pepper -Ginsenosides: active components of ginseng -Silymarin -Allicin -Lycopene -Ellagic acid -Caffeic acid phenethyl ester -flavopiridol -oleandrin -Ursolic acid -butein -Betulinic acid |
| 4792- | Lyco, | A Comprehensive Review on the Molecular Mechanism of Lycopene in Cancer Therapy |
| - | Review, | Var, | NA |
| 1708- | Lyco, | The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies |
| - | Review, | Var, | NA |
| 1714- | Lyco, | Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load |
| - | in-vitro, | Ovarian, | OV-MZ-6 | - | in-vivo, | NA, | NA |
| 1715- | Lyco, | Pro-oxidant Actions of Carotenoids in Triggering Apoptosis of Cancer Cells: A Review of Emerging Evidence |
| - | Review, | Var, | NA |
| 8516- | MAG, | Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma |
| - | in-vitro, | Melanoma, | NA |
| - | vitro+vivo, | CRC, | HT-29 | - | in-vitro, | Colon, | CT26 |
| 4514- | MAG, | Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential |
| - | Review, | Var, | NA |
| 4535- | MAG, | 5-FU, | Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K/AKT/mTOR and EMT pathways |
| - | in-vitro, | Cerv, | NA |
| 4530- | MAG, | Magnolol inhibits cancer stemness and IL-6/Stat3 signaling in oral carcinomas |
| - | in-vitro, | Oral, | NA |
| 4518- | MAG, | Cisplatin, | Evaluating the Magnolol Anticancer Potential in MKN-45 Gastric Cancer Cells |
| - | in-vitro, | GC, | MKN45 |
| 8568- | Matr, | Matrine induces apoptosis via targeting CCR7 and enhances the effect of anticancer drugs in non-small cell lung cancer in vitro |
| - | in-vitro, | NSCLC, | A549 |
| 8577- | Matr, | Cisplatin, | Meta analysis of compound matrine injection combined with cisplatin chemotherapy for advanced gastric cancer |
| - | Review, | GC, | NA |
| 8528- | Matr, | Cisplatin, | Matrine targets Enolase 1 and regulates the glycolysis-lactylation axis to enhance cisplatin sensitivity in triple-negative breast cancer |
| - | vitro+vivo, | BC, | NA |
| 8526- | Matr, | A Systematic Review of the Pharmacology, Toxicology and Pharmacokinetics of Matrine |
| - | Review, | Nor, | NA |
| 8544- | Matr, | Matrine in Liver Diseases: Mechanistic Insights and Therapeutic Potential |
| - | Review, | BC, | NA |
| 8560- | Matr, | Matrine: A Promising Natural Product With Various Pharmacological Activities |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA | - | Review, | Var, | NA |
| 8557- | Matr, | Effects of matrine in combination with cisplatin on liver cancer |
| - | in-vivo, | Liver, | HepG2 |
| 8555- | Matr, | Matrine Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review |
| - | Review, | Var, | NA |
| 8631- | MBZ, | BEV, | Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer |
| - | Trial, | CRC, | NA |
| 8641- | MBZ, | ONC201, | The therapeutic potential of repurposed mebendazole, alone and in synergistic combination with ONC201, in the treatment of diffuse midline glioma |
| - | in-vitro, | GBM, | NA |
| 8653- | MBZ, | Cisplatin, | Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC) |
| - | in-vitro, | HNSCC, | CAL27 | - | in-vitro, | HNSCC, | SCC-154 |
| 8648- | MBZ, | Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature |
| - | Review, | Var, | NA |
| 8819- | MCP, | PacT, | Pectasol‐C Modified Citrus Pectin targets Galectin‐3‐induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids |
| - | in-vitro, | Ovarian, | SKOV3 |
| 8725- | MeJa, | Methyl jasmonate leads to necrosis and apoptosis in hepatocellular carcinoma cells via inhibition of glycolysis and represses tumor growth in mice |
| - | vitro+vivo, | HCC, | HCCLM3 | - | in-vitro, | Liver, | Bel-7402 | - | in-vitro, | Liver, | Hep3B | - | in-vitro, | HCC, | SMMC-7721 cell |
| 8719- | MeJa, | Cisplatin, | Rad, | Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiation |
| - | in-vitro, | Cerv, | SiHa | - | in-vitro, | Cerv, | CaSki | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | C33A |
| 8751- | MeSA, | PacT, | Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 8756- | MeSA, | THE MAIN CYTOTOXIC EFFECTS OF METHYLSELENINIC ACID ON VARIOUS CANCER CELLS |
| - | Review, | Var, | NA |
| 8749- | MeSA, | etoposide, | Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo |
| - | in-vivo, | Pca, | NA |
| 8747- | MeSA, | Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | Laryn, | FaDu | - | in-vitro, | Pca, | PC3 | - | in-vitro, | CRC, | HCT116 |
| 8760- | MeSA, | Cisplatin, | Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer |
| - | vitro+vivo, | Lung, | NA | - | in-vitro, | Pca, | NA |
| 8764- | MeSA, | Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition |
| - | in-vitro, | Lung, | A549 |
| 8707- | MET, | Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 8711- | MET, | https://pubmed.ncbi.nlm.nih.gov/42725610/ |
| - | Review, | Var, | NA |
| 2386- | MET, | Mechanisms of metformin inhibiting cancer invasion and migration |
| - | Review, | Var, | NA |
| 2371- | MET, | The role of pyruvate kinase M2 in anticancer therapeutic treatments |
| - | Review, | Var, | NA |
| 5803- | MET, | carbop, | Metformin, at Concentrations Corresponding to the Treatment of Diabetes, Potentiates the Cytotoxic Effects of Carboplatin in Cultures of Ovarian Cancer Cells |
| - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | SKOV3 |
| 5796- | MET, | Tumor, whole blood, plasma, and tissue concentrations of metformin in lung cancer patients |
| - | Human, | Lung, | NA |
| 5795- | MET, | Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Diabetic, | NA |
| 5800- | MET, | Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect |
| - | Review, | Var, | NA |
| 5246- | MF, | Chemo, | Non-ionizing Electromagnetic Radiation: A Study of Carcinogenic and Cancer Treatment Potential |
| - | in-vitro, | BC, | MCF7 |
| 2244- | MF, | Little strokes fell big oaks: The use of weak magnetic fields and reactive oxygen species to fight cancer |
| - | Review, | Var, | NA |
| 2251- | MF, | Rad, | BEMER Electromagnetic Field Therapy Reduces Cancer Cell Radioresistance by Enhanced ROS Formation and Induced DNA Damage |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | HNSCC, | UTSCC15 | - | in-vitro, | CRC, | DLD1 | - | in-vitro, | PC, | MIA PaCa-2 |
| 8483- | MF, | Magnetic Fields in Cancer Therapy: Mechanistic Insights, Signaling Pathways, and Evidence from Clinical and In Vitro Studies |
| - | Review, | Var, | NA |
| 8489- | MF, | Pulsed electromagnetic fields induce ferroptosis in osteosarcoma cells and promote osteogenic differentiation |
| - | in-vitro, | OS, | U2OS | - | in-vitro, | OS, | MG63 |
| 8486- | MF, | Silent forces, hidden currents: the influence of static magnetic field stimulation on tumor biophysics |
| - | Review, | Var, | NA |
| 8485- | MF, | doxoR, | Static magnetic field promotes the doxorubicin toxicity effects on osteosarcoma cells |
| - | in-vitro, | OS, | G292 |
| 8484- | MF, | doxoR, | Pulsed Electromagnetic Field Increases Doxorubicin-induced Mitotic Slippage in MDA-MB-231 Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 3457- | MF, | Cellular stress response to extremely low‐frequency electromagnetic fields (ELF‐EMF): An explanation for controversial effects of ELF‐EMF on apoptosis |
| - | Review, | Var, | NA |
| 3464- | MF, | Progressive Study on the Non-thermal Effects of Magnetic Field Therapy in Oncology |
| - | Review, | Var, | NA |
| 3486- | MF, | Pulsed electromagnetic field potentiates etoposide-induced MCF-7 cell death |
| - | in-vitro, | BC, | MCF-10AT |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1106 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid